BiVictriX secures US patent for lead cancer therapy BVX001
The patent belongs to the wider ‘Therapy’ patent family and is currently under review in eight countries globally. The patent provides broad protection for BiVictriX's lead therapeutic asset, BVX001, at the antigen level.
The patents granted in the United States safeguard a treatment that uses antibodies to target harmful cells alongside a substance that kills these cells. This treatment focuses on a specific combination of proteins called CD7 and CD33 found on the surface of the harmful cells.
It is primarily aimed at treating Acute Myeloid Leukaemia (AML), but also provides protection across any haematological cancer type which may be positive for CD7 and CD33.
In case other companies attempt to create similar treatments through different approaches, BiVictriX's patent provides a commercially favourable position.
BiVictriX received another Notice of Allowance from the Japanese Patent Office. This patent is expected to be granted in Japan soon, adding more protection for BVX001. The company is also pursuing approval for this patent in six more global locations, and more patent grants are anticipated in the coming months.
Tiffany Thorn, CEO of BiVictriX commented: "I am excited to announce that our first patent has been granted in the United States. This patent relates to our broadest patent family, providing robust protection for BVX001 at the antigen level, across multiple cancer types, and acts as a key milestone for the Company demonstrating the breadth of patent protection we can achieve with the Bi-Cygni® approach. This patent grant is expected to be the first of many as we continue to prosecute the wider patent family in seven further jurisdictions worldwide, creating a robust patent protected portfolio.”
View from Vox
BiVictriX remains well positioned in one of the fastest-growing markets in oncology, and the new US patent grant will significantly boost its pace of growth in the US market. The global precision oncology market size was valued at US$100.06 billion in 2022 and is projected to surpass US$258.35 billion by 2032, with the therapeutics segment contributing the largest revenue share of 72% in 2022.
BiVictriX’s Bi-Cygni® therapeutics technology identifies cancer-specific ‘fingerprints’- novel combinations of antigens that are co-expressed on cancer cells but largely absent on healthy cells.
Benefits offered by Bi-Cygni® therapeutics include significantly reduced toxicity enabling higher dosing and greater efficacy, with this reduced toxicity expanding options for combinatorial therapies. Combinatorial therapies decrease the chance a tumor will be resistant to the treatment.
BiVictriX is in an exciting position, now on the cusp of multiple patent grants across to globe, and one step closer to bringing its cutting-edge cancer treatment to patients.
shares jumped 7.69% on the announcement.
Follow BiVictriX for more News and Updates:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.